NYSE:OGN

Organon & Co. (OGN) Stock Forecast, Price & News

$16.65

-0.71 (-4.09%)

(As of 10:51 AM ET)

Compare

Today's Range: $16.62
▼
$17.25
50-Day Range: $16.59
▼
$23.77
52-Week Range: $16.42
▼
$32.43

Volume: 447,210 shs
Average Volume: 2.18 million shs
Market Capitalization: $4.26 billion

P/E Ratio: 5.64
Dividend Yield: 6.73%
Price Target: $28.25

Organon & Co. MarketRank™ Forecast

Analyst Rating: Hold
2.25 Rating Score
Upside/Downside: 66.5% Upside
$28.25 Price Target
Short Interest: Healthy
2.84% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.35
Upright™ Environmental Score
News Sentiment: 0.68
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 6.53%
From $4.29 to $4.57 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.03 out of 5 stars

Medical Sector

32nd out of 969 stocks

Pharmaceutical Preparations Industry

8th out of 453 stocks

3.1

Analyst's Opinion

Consensus Rating
Organon & Co. has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $28.25, Organon & Co. has a forecasted upside of 66.5% from its current price of $16.97.
Amount of Analyst Coverage
Organon & Co. has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.84% of the float of Organon & Co. has been sold short.
Short Interest Ratio / Days to Cover
Organon & Co. has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Organon & Co. has recently increased by 4.31%, indicating that investor sentiment is decreasing.

3.3

Dividend Strength

Dividend Leadership
Organon & Co. is a leading dividend payer. It pays a dividend yield of 6.45%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Organon & Co. does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Organon & Co. is 37.97%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Organon & Co. will have a dividend payout ratio of 24.51% next year. This indicates that Organon & Co. will be able to sustain or increase its dividend.

3.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Organon & Co. has received a 41.86% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Contraceptive implants", "Thiazide diuretics", "Simvastatin", "Losartan", "Ezetimibe", and "Rizatriptan" products. See details.
Environmental Sustainability
The Environmental Impact score for Organon & Co. is -2.35.

3.2

News and Social Media Coverage

News Sentiment
Organon & Co. has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Organon & Co. this week, compared to 3 articles on an average week.
Search Interest
40 people have searched for OGN on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
MarketBeat Follows
8 people have added Organon & Co. to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Organon & Co. insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.17% of the stock of Organon & Co. is held by insiders.
Percentage Held by Institutions
77.08% of the stock of Organon & Co. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Organon & Co. are expected to grow by 6.53% in the coming year, from $4.29 to $4.57 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Organon & Co. is 5.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 107.61.
Price to Earnings Ratio vs. Sector
The P/E ratio of Organon & Co. is 5.75, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 88.67.
Price to Earnings Growth Ratio
Organon & Co. has a PEG Ratio of 0.55. PEG Ratios below 1 indicate that a company could be undervalued.

See Top Rated MarketRank™ Stocks Here

About Organon & Co. (NYSE:OGN) Stock

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

OGN Price History

30 days | 90 days | 365 days | Advanced Chart

OGN Stock News Headlines

October 1, 2023 | marketbeat.com

Drugs ‘n Diapers: 5 Dividends Up to 5.9%

September 27, 2023 | tmcnet.com

Organon Recognized on Fortune's 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice

October 2, 2023 | PressReach (Ad)

Nuclear Revival Creates Opportunities for Uranium

Uranium companies set to benefit from increased demand for clean energy.

September 27, 2023 | finance.yahoo.com

Organon Recognized on Fortune’s 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice

September 26, 2023 | finance.yahoo.com

On World Contraception Day, Organon Canada Declares Support for Universal Access to Contraception in Canada

September 24, 2023 | americanbankingnews.com

Barclays Begins Coverage on Organon & Co. (NYSE:OGN)

September 14, 2023 | finance.yahoo.com

First Real-World Observational Study of the JADA® System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG’s Obstetrics & Gynecology

September 10, 2023 | seekingalpha.com

6% Yield And Significantly Undervalued: A Closer Look At Organon

October 2, 2023 | Wall Street Fundamentals (Ad)

How is This "Hidden Gem" Thriving in a Turbulent Market?

While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.

September 5, 2023 | finance.yahoo.com

Organon Bolsters Research & Development Expertise with Two Leadership Appointments

August 13, 2023 | finance.yahoo.com

Dividend Investors: Don't Be Too Quick To Buy Organon & Co. (NYSE:OGN) For Its Upcoming Dividend

August 11, 2023 | uk.finance.yahoo.com

Organon (NYSE:OGN) Will Pay A Dividend Of $0.28

August 10, 2023 | seekingalpha.com

Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk

August 8, 2023 | msn.com

Organon jumps ~9% on strong Q2 driven by higher contraceptive sales, growth in biosimilars

August 8, 2023 | news.yahoo.com

Organon results beat estimates on demand for women heath products, biosimilars

August 8, 2023 | finance.yahoo.com

Organon Reports Results for the Second Quarter Ended June 30, 2023

August 8, 2023 | seekingalpha.com

Organon & Co. 2023 Q2 - Results - Earnings Call Presentation

August 1, 2023 | finance.yahoo.com

Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar

July 27, 2023 | finance.yahoo.com

Organon & Co (OGN) Dropped After Reporting Q1 Revenue

July 19, 2023 | markets.businessinsider.com

Organon & Company hosts conference call for investors

July 17, 2023 | msn.com

Organon: Big Dividend And Upside Potential

July 17, 2023 | finance.yahoo.com

Organon To Report Second Quarter Results and Host Conference Call on August 8, 2023

July 16, 2023 | seekingalpha.com

Organon & Co.: A Tough Spot To Be In Right Now

July 14, 2023 | finance.yahoo.com

Following a 32% decline over last year, recent gains may please Organon & Co. (NYSE:OGN) institutional owners

July 10, 2023 | barrons.com

S&P 500 Futures Flat in Premarket Trading; Icahn Enterprises, Organon Lead

July 5, 2023 | finance.yahoo.com

REPEAT/Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator

July 5, 2023 | finance.yahoo.com

Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis

See More Headlines

Receive OGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter.

OGN Company Calendar

Last Earnings: 8/08/2023
Ex-Dividend for 9/14 Dividend: 8/17/2023
Dividend Payable: 9/14/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:OGN
CUSIP: N/A
CIK: 1821825
Web: www.organon.com
Phone: 551-430-6900
Fax: N/A
Employees: 10,000
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $28.25
High Stock Price Forecast: $33.00
Low Stock Price Forecast: $25.00
Forecasted Upside/Downside: +62.7%
Consensus Rating: Hold
Rating Score (0-4): 2.25
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.95
Trailing P/E Ratio: 5.88
Forward P/E Ratio: 4.05
P/E Growth: 0.55
Net Income: $917 million
Net Margins: 12.22%
Pretax Margin: 14.30%
Return on Equity: -142.40%
Return on Assets: 10.73%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.66
Quick Ratio: 1.16

Sales & Book Value

Annual Sales: $6.17 billion
Price / Sales: 0.72
Cash Flow: $5.88 per share
Price / Cash Flow: 2.95
Book Value: ($3.51) per share
Price / Book: -4.95

Miscellaneous

Outstanding Shares: 255,570,000
Free Float: 252,578,000
Market Cap: $4.44 billion
Optionable: Not Optionable
Beta: 0.91

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Kevin Ali (Age 63)
CEO & Director
Comp: $3.96M

Mr. Matthew M. Walsh (Age 56)
Exec. VP & CFO
Comp: $1.84M

Ms. Susanne Gabriele Fiedler (Age 55)
Exec. VP & Chief Commercial Officer
Comp: $1.44M

Dr. Sandra Milligan J.D. (Age 59)
M.D., Exec. VP and Head of R&D
Comp: $1.6M

Mr. Joseph T. Morrissey Jr. (Age 58)
Exec. VP and Head of Manufacturing & Supply
Comp: $1.54M

Ms. Rachel A. Stahler (Age 47)
Exec. VP & Chief Information Officer

Ms. Jennifer Halchak
VP of Investor Relations

Mr. Kirke Weaver (Age 50)
Exec. VP, Gen. Counsel & Corp. Sec.

Mr. Aaron Falcione (Age 52)
Exec. VP & Chief HR Officer

Mr. Vittorio Nisita (Age 55)
Exec. VP & Head of Global Bus. Services

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

OGN Stock - Frequently Asked Questions

Should I buy or sell Organon & Co. stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organon & Co. in the last twelve months. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" OGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OGN, but not buy additional shares or sell existing shares.
View OGN analyst ratings or view top-rated stocks.
What is Organon & Co.'s stock price forecast for 2023?: 4 brokerages have issued 12-month price objectives for Organon & Co.'s shares. Their OGN share price forecasts range from $25.00 to $33.00. On average, they predict the company's share price to reach $28.25 in the next twelve months. This suggests a possible upside of 62.7% from the stock's current price.
View analysts price targets for OGN or view top-rated stocks among Wall Street analysts.
How have OGN shares performed in 2023?: Organon & Co.'s stock was trading at $27.93 at the beginning of 2023. Since then, OGN stock has decreased by 37.8% and is now trading at $17.36.
View the best growth stocks for 2023 here.
When is Organon & Co.'s next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our OGN earnings forecast.
How were Organon & Co.'s earnings last quarter?: Organon & Co. (NYSE:OGN) posted its quarterly earnings data on Tuesday, August, 8th. The company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.97 by $0.34. The business earned $1.61 billion during the quarter, compared to analysts' expectations of $1.57 billion. Organon & Co. had a net margin of 12.22% and a negative trailing twelve-month return on equity of 142.40%. The company's revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.25 earnings per share.
Read the conference call transcript.
How often does Organon & Co. pay dividends? What is the dividend yield for Organon & Co.?: Organon & Co. declared a quarterly dividend on Tuesday, August 8th. Investors of record on Friday, August 18th will be paid a dividend of $0.28 per share on Thursday, September 14th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 6.45%. The ex-dividend date of this dividend is Thursday, August 17th.
Read our dividend analysis for OGN.
What ETFs hold Organon & Co.'s stock?: ETFs with the largest weight of Organon & Co. (NYSE:OGN) stock in their portfolio include Invesco S&P Spin-Off ETF (CSD), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Emerge EMPWR Sustainable Dividend Equity ETF (EMCA), Invesco S&P 500 High Dividend Low Volatility ETF (SPHD), First Trust Nasdaq Pharmaceuticals ETF (FTXH), VanEck Pharmaceutical ETF (PPH) and iShares U.S. Pharmaceuticals ETF (IHE).

Is Organon & Co. a good dividend stock?: Organon & Co. (NYSE:OGN) pays an annual dividend of $1.12 per share and currently has a dividend yield of 6.45%. OGN has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 37.97%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, OGN will have a dividend payout ratio of 24.51% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for OGN.
What guidance has Organon & Co. issued on next quarter's earnings?: Organon & Co. updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $6.25 billion-$6.45 billion, compared to the consensus revenue estimate of $6.28 billion.
What is Organon & Co.'s stock symbol?: Organon & Co. trades on the New York Stock Exchange (NYSE) under the ticker symbol "OGN."
How do I buy shares of Organon & Co.?: Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Organon & Co.'s stock price today?: One share of OGN stock can currently be purchased for approximately $17.36.
How much money does Organon & Co. make?: Organon & Co. (NYSE:OGN) has a market capitalization of $4.44 billion and generates $6.17 billion in revenue each year. The company earns $917 million in net income (profit) each year or $2.95 on an earnings per share basis.
How many employees does Organon & Co. have?: The company employs 10,000 workers across the globe.
How can I contact Organon & Co.?: Organon & Co.'s mailing address is 2000 Galloping Hill Road, Kenilworth, New Jersey 07033. The official website for the company is www.organon.com. The company can be reached via phone at 551-430-6900 or via email at investor_relations@organon.com.

This page (NYSE:OGN) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial